Pure Biologics stock pursues Huntington gene therapy plan

Pure Biologics stock is tied to multiQure's plan for an experimental Huntington gene therapy application after a September 28, 2026 letter of intent with Mazowiecki Szpital Bródnowski and Professor Miros?aw Z?bek, according to Bankier.pl. The agreement covers project documentation, hospital infrastructure and the medical team needed for a potential first patient application.

Huntington program enters preparation

The letter is a development step rather than a treatment launch. The parties still need a separate operational agreement, bioethics opinions and other regulatory approvals before patient qualification or treatment can begin, the September 28, 2026 filing reported by Bankier.pl states. Professor Z?bek previously participated in uniQure's AMT-130 Huntington disease program, according to the same filing.

New identity and larger share base

The issuer registered its name change from Pure Biologics to MultiQure on August 4, 2026, while Biofund Capital Management became the largest shareholder with 49.99 percent of voting rights, according to StockWatch. The September capital increase added 66.80 million shares, with 50.00 million Series S shares and 16.80 million Series R shares, according to Puls Biznesu.

Q1 figures show development risk

For the first quarter of 2026, revenue was PLN 0, EBITDA was PLN -1.70 million and net income was PLN -2.24 million, according to stockd. The combination of zero revenue and negative operating results places the Huntington program in a financing and execution phase rather than a commercial revenue phase.

Development remains the market test

The September 28, 2026 agreement gives the project a defined hospital setting and clinical leadership, while the Q1 2026 figures show the financial distance to commercialization. The next measurable milestones are regulatory preparation, vector manufacturing and an executed agreement for the experimental application.